Network meta-analysis showed supporting evidence that fluvastatin and atorvastatin (lipophilic) had a higher cumulative probability of reducing CRP in COPD patients than rosuvastatin (hydrophilic) (97.7% for fluvastatin, 68.9% for atorvastatin, and 49.3% for rosuvastatin) (28). The gene discussed is CRP; the disease is chronic obstructive pulmonary disease.